Keith Humphreys
Keith Humphreys is a professor of psychiatry and behavioral sciences at the Stanford School of Medicine. His work focuses on addiction treatment, behavioral health, and drug policy. His published research examines interventions and recovery programs for substance use disorders—including opioids, alcohol, and stimulants—as well as associated mortality and overdose risks.
Fact-checked episodes
Publications
- High-risk emergency department visits and risk of all-cause mortality, suicide, and fatal overdose among US military veterans.
- Who participates in collegiate recovery programs? A survey of students in the US and Canada.
- Potential health impacts of comprehensive access to opioid use disorder treatment in United States correctional facilities: A synthetic analysis.
- Effects of Intermittent Theta Burst on Multiple Measures of Craving in Those With Alcohol Use Disorder.
- Strengthening authorship transparency for letters to the editor.
- Did the illicit fentanyl trade experience a supply shock?
- Electronic Intervention for Patient-Managed Benzodiazepine Tapering: A Randomized Clinical Trial.
- Opioid use disorder of any severity is associated with increased suicidality.
- Substance use and treatment utilization patterns of working-age American men who were not in employment, education, or training (NEET) during the COVID-19 pandemic.
- Costs and Outcomes in Telemedicine-Can "House Calls" Make Sense and Cents?
- Spirituality and Harmful or Hazardous Alcohol and Other Drug Use: A Meta-Analysis of Longitudinal Studies.
- Cost-effectiveness of contingency management for methamphetamine use disorder: A model-based analysis.
- The interaction of age and total lifetime drinks is associated with regional cortical perfusion and thickness in healthy adults with low-level alcohol consumption.
- TikTok is a valuable data source for tracking the opioid crisis.
- Substance use and treatment utilization patterns of working-age American men who were not in employment, education, or training (NEET) during the COVID-19 pandemic.
- Trends of Fentanyl and Oxycodone Use in Australia (2018-2022) in National Prescription and Wastewater Data Sets.
- Can the Contract Between Addiction Scientists and Policymakers Be Restored to What It Was in Griffith Edwards' Time?
- In healthy adults with low-level alcohol intake greater age and lifetime alcohol consumption are associated with poorer manual dexterity and higher lifetime consumption is related to worse postural stability.
- Crafting effective regulatory policies for psychedelics: What can be learned from the case of cannabis?
- Therapeutic Potential of Psychedelic Drugs: Navigating High Hopes, Strong Claims, Weak Evidence, and Big Money.
- Characterizing Collegiate Recovery Programs in the United States and Canada: A Survey of Program Directors.
- Evaluating a 30-day alcohol abstinence challenge in heavy-drinking individuals with and without chronic pain: Feasibility, safety, and perceived benefits.
- Disentangling debate about therapeutic and recreational use of psychedelics.
- Recent Drug Overdose Mortality Decline Compared With Pre-COVID-19 Trend.
- Trends in Psychiatrist-Led Care for Medicare Part B Enrollees.
- Towards opioid access without excess.
- Intermittent theta burst to the left dorsolateral prefrontal cortex promoted decreased alcohol consumption and improved outcomes in those with alcohol use disorder: A randomized, double-blind, placebo-controlled clinical trial.
- Which social media platforms facilitate monitoring the opioid crisis?
- Monitoring the opioid epidemic via social media discussions.
- Association Between Opioid Use Disorder and Healthcare Spending and Utilization in Emergency Surgical Patients: A Retrospective Analysis Using Commercial Claims.
- Effects of intermittent theta burst to the left dorsolateral prefrontal cortex on brain volumes and neurometabolites in people with alcohol use disorder: a preliminary investigation.
- Effectiveness of Mutual Help Groups for Illicit Drug Use Disorders: A Review of the Current Literature.
- Predicting treatment retention in medication for opioid use disorder: a machine learning approach using NLP and LLM-derived clinical features.
- Evaluating the impact of data biases on algorithmic fairness and clinical utility of machine learning models for prolonged opioid use prediction.
- Are observation codes underused for emergency psychiatric patients with an extended length of stay? A retrospective commercial claims analysis from 2016 to 2022.
- Substance use and treatment utilization patterns of working-age American men who were not in employment, education, or training (NEET) during the COVID-19 pandemic.
- Does the advent of depot therapy represent a step change in our understanding of opioid use disorder and its treatment?
- Leadership Styles Experienced During Military Service Predict Later Anhedonic Depressive Symptoms and Self-Efficacy in Veterans With Alcohol Use Disorder.
- A pilot, randomized clinical trial: Left dorsolateral prefrontal cortex intermittent theta burst stimulation improves treatment outcomes in veterans with alcohol use disorder.
- Estimated effectiveness and cost-effectiveness of opioid use disorder treatment under proposed U.S. regulatory relaxations: A model-based analysis.
- Towards global model generalizability: independent cross-site feature evaluation for patient-level risk prediction models using the OHDSI network.
- A Randomized Controlled Trial of a Pay-for-Performance Initiative to Reduce Costs of Care for High-Need Psychiatric Patients.
- Progress and Challenges in Medicaid-Financed Care of Substance Use Disorder.
- Predictability of buprenorphine-naloxone treatment retention: A multi-site analysis combining electronic health records and machine learning.
- Social prescribing of Alcoholics Anonymous in general practice.
- Improving postsurgical fall detection for older Americans using LLM-driven analysis of clinical narratives.
- Which social media platforms facilitate monitoring the opioid crisis?
- Cost-effectiveness of office-based buprenorphine treatment for opioid use disorder.
- State Cannabis Legalization and Psychosis-Related Health Care Utilization.
- Clinical Research: the Samples Are Narrow, But at Least the Conclusions Are Broad.
- Twenty-Year Trends in Drug Overdose Fatalities Among Older Adults in the US.
- "Safe Supply" Initiatives: Are They a Recipe for Harm Through Reduced Health Care Input and Supply-Induced Toxicity and Overdose?
- Cost-effectiveness of Increasing Buprenorphine Treatment Initiation, Duration, and Capacity Among Individuals Who Use Opioids.
- The Evolution of Telepsychiatry for Substance Use Disorders During COVID-19: a Narrative Review.
- Adapting a Telephone-Based, Dyadic Self-management Program to Be Delivered Over the Web: Methodology and Usability Testing.
- Healthcare costs and use before and after opioid overdose in Veterans Health Administration patients with opioid use disorder.
- How Addiction handles disagreements over potentially harmful terminology.
- Promises and perils of the FDA's over-the-counter naloxone reclassification.
- Prediction of opioid-related outcomes in a medicaid surgical population: Evidence to guide postoperative opiate therapy and monitoring.
- Long-Term Effects of Increasing Buprenorphine Treatment Seeking, Duration, and Capacity on Opioid Overdose Fatalities: A Model-based Analysis.
- Understanding predictors of mental health and substance use treatment utilization among US adults: A repeated cross-sectional study.
- Drug-related deaths among housed and homeless individuals in the UK and the USA: comparative retrospective cohort study.
- A practical strategy for increasing representation of women in research.
- Predicting premature discontinuation of medication for opioid use disorder from electronic medical records.
- Responding to the opioid crisis in North America and beyond: recommendations of the Stanford-Lancet Commission.
- Sociodemographic and geographic disparities in excess fatal drug overdoses during the COVID-19 pandemic in California: A population-based study.
- Responding to 100 000 annual drug overdose deaths in the United States: a special section of commentaries.
- Synthesizing advice to the United States from other nations that have experienced drug epidemics.
- Modeling the evolution of the US opioid crisis for national policy development.
- Reducing opioid use disorder and overdose deaths in the United States: A dynamic modeling analysis.
- The impact of the COVID-19 pandemic on addictive disorders-an update.
- Promoting benzodiazepine cessation through an electronically-delivered patient self-management intervention (EMPOWER-ED): Randomized controlled trial protocol.
- Adapting the Eliminating Medications Through Patient Ownership of End Results Protocol to Promote Benzodiazepine Cessation Among US Military Veterans: Focus Group Study With US Military Veterans and National Veterans Health Administration Leaders.
- Prescription quantity and duration predict progression from acute to chronic opioid use in opioid-naïve Medicaid patients.
- Is good science leading the way in the therapeutic use of psychedelic drugs?
- A literature review of the impact of exclusion criteria on generalizability of clinical trial findings to patients with chronic pain.
- Changes in postoperative opioid prescribing across three diverse healthcare systems, 2010-2020.
- Policy Responses to the Addiction Crisis.
- Evaluation of State Cannabis Laws and Rates of Self-harm and Assault.
- Cost-effectiveness of Treatments for Opioid Use Disorder.
- Comparison of Treatments for Cocaine Use Disorder Among Adults: A Systematic Review and Meta-analysis.
- College programming for students in addiction recovery: A PRISMA-guided scoping review.
- Robustness of estimated access to opioid use disorder treatment providers in rural vs. urban areas of the United States.
- Substance Use, PTSD Symptoms, and Suicidal Ideation Among Veteran Psychiatry Inpatients: A Latent Class Trajectory Analysis.
- Effectiveness of Policies for Addressing the US Opioid Epidemic: A Model-Based Analysis from the Stanford-Lancet Commission on the North American Opioid Crisis.
- Our Other Epidemic: Addiction.